Oxford BioDynamics invited to join FNIH steering committee

Josh White WebFG News | 20 Apr, 2017 16:48 | | |

Astrazeneca

Oxford Biodynamics

186.00

17:18 15/12/17
-2.30%
-4.38
  • 1,014.92
  • 0.01%0.13
  • Max: 1,016.55
  • Min: 1,013.24
  • Volume: 0
  • MM 200 : n/a
17:25 15/12/17

Discovery and development of novel epigenetic biomarkers-focussed biotechnology company Oxford BioDynamics announced on Thursday that itself and Dr Claudio Carini, a member of company’s scientific advisory panel, had been invited to join the Foundation for the National Institutes of Health Biomarkers Consortium as a member of the Cancer, Inflammation & Immunity, and Neuroscience Steering Committees.

The AIM-traded firm said the Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH that endeavours to discover, develop, and seek regulatory approval for biological markers, known as biomarkers, to support new drug development, precision medicine, and medical diagnostics.

It said the Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by The Biomarkers Consortium, as well as overseeing each individual project under its purview.

The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit and advocacy organisations, the board explained.

Dr Carini had prior experience as a member of the FNIH Biomarkers Consortium Steering Committees, as well as having consulted and sat on many other distinguished international advisory boards and committees including the Medical Research Council, Innovative Medicine Initiative and the PML Consortium, it added.

“We are delighted that Claudio will be joining these prestigious biomarker committees,” said Oxford BioDynamics CEO Christian Hoyer Millar.

“The FNIH Biomarkers Consortium aims to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease, and this is a goal that is shared by Oxford BioDynamics.

“We believe that becoming a member of these important FNIH committees will be beneficial as we continue to progress towards our strategic aim of becoming the industry standard for epigenetic biomarker discovery.”

More news

15 Dec London close: Footsie gains as pound drops, Wall Street hits fresh highs

The top flight index recovered some ground on Friday, but mostly on account of weakness in Sterling after German Chancellor Angela Merkel reportedly echoed other European Union officials, saying "the most difficult phase is ahead of us".

15 Dec Week ahead: US data, Catalan elections in focus

The focus in the coming week will continue to be on the ebb and flow of data out of the US, including Republicans' progress on securing passage of their tax cuts.

15 Dec US open: Stocks jump as Republicans move to secure passage of tax cuts

Wall Street is heading higher again on Friday amid news that Republicans were tweaking their proposed tax cuts in order to secure prompt passage of the US tax bill.

15 Dec Airbus chief executive to step down in board shake-up

The chief executive of French planemaker Airbus will step down from his position in 2019 as the company announced a major shake-up of its management team.

15 Dec FTSE 250 movers: TalkTalk rises but Serco gives back gains

London’s FTSE 250 was up 0.1% to 20,023.23 in afternoon trade on Friday as the Christmas lull kicked in.

15 Dec US industrial production rises slightly less than expected in November

Industrial production in the States rose slightly less quickly than expected last month, despite higher output of business equipment and materials.

15 Dec Strategic Minerals renegotiates acquisition of Leigh Creek Copper Mine

Diversified mineral production and development company Strategic Minerals announced on Friday that, after the successful completion of technical and financial due diligence on the Leigh Creek Copper Mine company, it has agreed to continue with the acquisition on renegotiated terms.

15 Dec FTSE 100 movers: Sky jumps but retailers retreat on H&M sales

London’s FTSE 100 was up 0.3% to 7,469.23 in quiet afternoon trade on Friday.

15 Dec Gfinity partners with Microsoft for next Halo World Championship

International esports entertainment group Gfinity has been named as a preferred event partner to Microsoft for the forthcoming ‘Halo World Championship 2018’ for the next season, it announced on Friday.

15 Dec Hutchison Chi-Med begins fruquintinib trial in US

Hutchison China MediTech, known as Chi-Med, has initiated the United States Phase I bridging clinical trial of fruquintinib, it announced on Friday.